We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Improving hepatocyte activity, pooling and lab efficiency

Video   Oct 03, 2018

 

Aired: Thursday, September 27, 2018
Presenter: Chris Bohl, Ph.D., Global Technical Support Manager

Synopsis:
CryostaX® hepatocytes are created using a patented process that produces unique single-donor cell pellets. This format allows for distinct benefits to hepatocyte performance, efficiency in the lab, and test system design, precipitating the potential discontinuation of cryopreserved hepatocytes prepared from traditional methods. This webinar will discuss the technology, its optimal utilization and benefits...

Key concepts discussed in this webinar will include:
- How single-freeze hepatocyte pellets preserve higher metabolic activity, longer
- The benefits of skipping the thaw step
- Pellet pooling versatility (demographics for human pools; larger rodent lot sizes)
- Patented cryopreservation technology overview

Slides:
https://www.xenotech.com/webinar-slides/cryostax-pellets-improving-hepatocyte-performance.pdf

Questions or requests:
https://www.xenotech.com/contact-us

 
More Information
 
 
 

Recommended Videos

Ulcerative Colitis: Fresh Approaches to Taming Inflammation

Video

This animation explores how insights into the immunobiology of ulcerative colitis are helping researchers to develop innovative treatments.

WATCH NOW

The Advantages of Machine Learning and Artificial Intelligence in the Drug Discovery Process

Video

Dr Ola Engkvist, AstraZeneca, explains how the drug discovery process benefits from artificial intelligence and machine learning.

WATCH NOW

Applying Deep Learning Architectures to de novo Molecular Drug Design

Video

Dr Ola Engkvist, AstraZeneca, outlines how deep learning architectures are being applied to drug discovery.

WATCH NOW

 

Like what you just watched? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE